2012
DOI: 10.1093/rheumatology/kes069
|View full text |Cite
|
Sign up to set email alerts
|

Juvenile idiopathic arthritis-associated uveitis complicated by glaucoma and Brown’s syndrome

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

0
3
0

Year Published

2013
2013
2023
2023

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(3 citation statements)
references
References 7 publications
0
3
0
Order By: Relevance
“… 10 13 The underlying pathogenesis of Brown syndrome in these immunological disorders is not fully understood; however, most theories suggest a deposition of autoimmune complexes in the synovial membranes and tendon sheaths causing tenosynovitis and thickening of the tissues surrounding the superior oblique muscle tendon, impairing its movement within the trochlea and causing the hallmark picture of limited elevation on adduction. 14 , 15…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“… 10 13 The underlying pathogenesis of Brown syndrome in these immunological disorders is not fully understood; however, most theories suggest a deposition of autoimmune complexes in the synovial membranes and tendon sheaths causing tenosynovitis and thickening of the tissues surrounding the superior oblique muscle tendon, impairing its movement within the trochlea and causing the hallmark picture of limited elevation on adduction. 14 , 15…”
Section: Discussionmentioning
confidence: 99%
“…[10][11][12][13] The underlying pathogenesis of Brown syndrome in these immunological disorders is not fully understood; however, most theories suggest a deposition of autoimmune complexes in the synovial membranes and tendon sheaths causing tenosynovitis and thickening of the tissues surrounding the superior oblique muscle tendon, impairing its movement within the trochlea and causing the hallmark picture of limited elevation on adduction. 14,15 The Oxford-AstraZeneca COVID-19 vaccine has first been approved for use in the UK vaccination program in December 2020, followed by the European Medicines Agency, the Australian Therapeutic Goods Administration, and the World Health Organization in early 2021. The vaccine uses an altered adenoviral vector vaccine to induce an immune response against SARS-CoV-2.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation